Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86 Leukemia 50 Gastrointestinal Stromal Tumors 41 Leukemia, Myeloid, Chronic-Phase 28 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Blast Crisis 17 Philadelphia Chromosome 13 Brain Neoplasms 12 Sarcoma 10 Leukemia, Myeloid, Acute 10 Glioblastoma 10 Lung Neoplasms 9 Leukemia, Myeloid, Accelerated Phase 9 Gliosarcoma 9 Prostatic Neoplasms 8 Neoplasms 7 Neoplasm Metastasis 7 Glioma 7 Oligodendroglioma 6 Melanoma 6 Leukemia, Myelomonocytic, Chronic 6 Dermatofibrosarcoma 6 Astrocytoma 6 Small Cell Lung Carcinoma 5 Recurrence 5 Primary Myelofibrosis 5 Polycythemia Vera 5 Ovarian Neoplasms 5 Leukemia, Myeloid 5 Central Nervous System Neoplasms 5

Interventions

Sirolimus 6 Everolimus 5 saracatinib 1 nintedanib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × Imatinib Mesylate × Clear all

NCT03131999 2020-06-16

LAMP-1

Medical University of South Carolina

Phase 1/2 Completed

18 enrolled 7 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡